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Abstract
Introduction
The immune system acts on different metabolic tissues that are implicated in the pathogene-
sis of nonalcoholic fatty liver disease (NAFLD). Leptin and linoleic acid have the ability to
potentially affect immune cells, whereas curcumin is a known natural polyphenol with antiox-
idant and anti-inflammatory properties.
Aims
This study was designed to evaluate the pro-inflammatory and pro-oxidant effects of leptin
and linoleic acid on immune cells from patients with NAFLD and to corroborate the modula-
tory effects of curcumin and its preventive properties against the progression of NAFLD
using a high-fat diet (HFD)-induced NAFLD/nonalcoholic steatohepatitis mouse model.
Results
The ex vivo experiments showed that linoleic acid increased the production of reactive oxy-
gen species in monocytes and liver macrophages, whereas leptin enhanced tumor necrosis
factor-α (TNF-α) production in monocytes and interferon-γ production in circulating CD4+
cells. Conversely, oral administration of curcumin prevented HFD-induced liver injury,
metabolic alterations, intrahepatic CD4+ cell accumulation and the linoleic acid- and leptin-
induced pro-inflammatory and pro-oxidant effects on mouse liver macrophages.
Conclusion
Our findings provide new evidence for the therapeutic potential of curcumin to treat human
NAFLD. However, the development of a preventive treatment targeting human circulating
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monocytes and liver macrophages as well as peripheral and hepatic CD4+ cells requires
additional research.
Introduction
The spectrum of nonalcoholic fatty liver disease (NAFLD) ranges from simple steatosis to non-
alcoholic steatohepatitis, liver fibrosis, cirrhosis, and hepatocellular carcinoma [1]. Many dys-
regulated factors involved in NAFLD act in parallel, particularly gut-derived and adipose
tissue factors, to finally result in liver inflammation [2]. Kupffer cell activation plays a central
role in NAFLD progression through the production of pro-inflammatory cytokines and type 1
interferon (IFN), the promotion of leukocyte infiltration, and fibrogenesis [3]. When baseline
inflammation is present, insulin-resistant hepatocytes increase cysteine-cysteine motif chemo-
kine ligand 20 (CCL20) expression, which subsequently recruits lymphocytes into the liver [4].
The immune system plays roles in the metabolic pathways of various tissues implicated in
the pathogenesis of nonalcoholic steatohepatitis, such as liver and adipose tissue [5]. Leptin is
an anorexigenic and pro-inflammatory adipokine that links energy homeostasis to immune
system activity [6,7]. The pleiotropic function of leptin is mediated by its binding to leptin
receptors in different immune cell types [8]. Due to its role in regulating both arms of the
immune response [9], leptin strongly influences inflammation and autoimmune-related disor-
ders [10]. In the context of NAFLD, leptin has potential dual activity in exerting an early pro-
tective anti-steatotic response as well as late pro-inflammatory and pro-fibrogenic effects [11].
Leptin-induced oxidative stress and inflammation mediated by Kupffer cells promote the pro-
gression of nonalcoholic steatohepatitis [12]; additionally, reports have indicated that oxidative
stress is the source of humoral and cellular immunological mechanisms that may contribute to
NAFLD progression [13].
Increase in the plasma free fatty acid concentration in healthy individuals were associated
with the induction of pro-inflammatory changes and oxidative stress in circulating mononu-
clear cells [14]. NAFLD progression in humans is characterized by systemic changes in lipid
metabolism involving most hepatic and circulating lipids, particularly alterations in the pro-
duction of n-6 polyunsaturated fatty acids [15, 16]. It was established that ox-NASH, a risk
score that incorporates the plasma concentration of linoleic acid and one of its oxidation prod-
ucts, correlates with the primary altered histological features and with the severity of NAFLD
[17, 18]. Thus, the inflammatory response of mononuclear cells exposed to linoleic acid is
potentially associated with NAFLD progression.
Curcumin, a pigment extracted from the rhizomes of Curcuma longa, has strong antioxi-
dant, anti-inflammatory and anti-cancer properties. Curcumin acts by either directly interact-
ing with numerous molecular targets or altering gene expression and signaling pathways [19].
It can prevent obesity and obesity-related chronic diseases [20, 21] and has anti-inflammatory
properties on monocytes and macrophages [22] as well as anti-proliferative effects on T cells
[23].
Under the hypothesis that a prevailing inflammatory state in NAFLD would be amplified
by linoleic acid and leptin, we aimed to evaluate the effects of these molecules on the produc-
tion of cytokines and reactive oxygen species in immune cells from patients with NAFLD.
Given that curcumin may protect against linoleic acid- and leptin-induced inflammatory sti-
muli, we assessed the ex vivo modulatory effects of curcumin on human immune cells and its
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potential protective effects against NAFLD progression in a high-fat diet (HFD)-induced
NAFLD/nonalcoholic steatohepatitis mouse model.
Materials and methods
Ex vivo studies in human NAFLD
Patients and general procedures. Blood samples and liver biopsies were collected from
72 adult patients with confirmed NAFLD at the Gastroenterology Divisio´n of the Jose´ de San
Martin (JSM) Clinical Hospital (Table 1). The experimental protocols and sample studies were
approved by the Ethics Committee of the JSM Clinical Hospital at the University of Buenos
Aires and followed the internationally endorsed standards as stated in the Declaration of Hel-
sinki. All subjects were informed of the aim of the study and gave their written informed con-
sent. Accordingly, we collected no more than 15 ml of blood from each patient for this project.
Unfortunately, the blood sample volume was insufficient to perform each assay in every sub-
ject, and the amount of liver biopsy tissue was inadequate for more than one assay per sample.
A diagnosis of NAFLD was based on daily alcohol consumption (<20 g/day), the absence
of other causes of liver disease, and scoring of macrovesicular steatosis, lobular inflammation
and ballooning degeneration [24].
Blood from 44 age-matched and metabolically healthy control individuals were recruited
among staff members at the Institute of Immunology, Genetics and Metabolism at JSM Clini-
cal Hospital. All the staff was given information regarding the study, and those who intended
to participate were told to contact the investigators. None of the control subjects used medica-
tions within 6 months previous to the study, consumed more than 20 g/day of alcohol, or had
a body mass index higher than 25 kg/m2. Additionally, we obtained biopsies from a second
Table 1. Demographic, anthropometric and biochemical baseline data of patients with NAFLD and control individuals.
Variable (unit) Control group #1 Control group #2 NAFLD
Gender 32 M/12 F 10 M/4 F 22 M/50 F
Age(years) 50.50±4.90 56.00±6.11 59.50±4.17
Body mass index(kg/m2) 23.90±1.06 24.31±3.10 32.41±1.52*
Waist Circumference (cm) 84.00±5.33 86.00±4.43 105.4±5.14**
HOMA-IR 1.31±0.32 ND 3.22±0.33**
Basal glucose (mg/dL) 93.50±1.10 93.60±2.91 95.83±6.99
Insulin (μU/mL) 5.43±0.62 ND 17.54±2.73
Total cholesterol (mg/dL) 174.50±4.12 170.00±2.22 198.8±13.30
Triglycerides(mg/dL) 111.00±3.01 109.01±4.30 165.8±25.70
Aspartate aminotransferases (IU/L) 24.00±0.62 ND 40.43±7.92
Alanineaminotransferases (IU/L) 25.00±0.71 ND 49.00±12.70
The individuals in control group #1 were recruited among staff members at the Institute of Immunology, Genetics and Metabolism at JSM Clinical Hospital.
We obtained biopsies from a second control group (control group #2) consisting of 14 individuals who underwent anti-reflux surgery or cholecystectomy at
the Gastroenterology Divisio´n of the JSM Clinical Hospital. Patients with NAFLD were recruited at the Gastroenterology Divisio´n of the Jose´ de San Martin
(JSM) Clinical Hospital. Abbreviations: M, males; F, females; ND: not determined. A body mass index between 25 and 29.9 was considered overweight,
whereas a value greater than 30 was considered obese. Fasting glucose and insulin were measured using commercial kits. HOMA-IR, homeostatic
assessment model for insulin resistance. HOMA-IR was calculated using the following formula with fasting values: HOMA-IR = [glucose (mg/dL) * insulin
(μU/mL)/405]. The reference ranges for total cholesterol and triglycerides are 150 to 199 mg/dL and 31 to 119 mg/dL, respectively. The normal alanine and
aspartate aminotransferase levels are32 and48 IU/L, respectively. The data are presented as the mean values ± SEM.
* p< 0.05,
** p< 0.01.
doi:10.1371/journal.pone.0172900.t001
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control group comprising 14 individuals who underwent either anti-reflux surgery or chole-
cystectomy at the Gastroenterology Divisio´n of the JSM Clinical Hospital (Table 1, control
groups #1 and #2). Liver biopsies from control group #2 were included to compare the infil-
trating cell subpopulations in the liver and the Th1 gene profile expression with those of
patients with NAFLD.
Fasting glucose and insulin levels were measured using commercially available kits. The
homeostatic assessment model for insulin resistance (HOMA-IR) was calculated using the fol-
lowing formula with fasting values: HOMA-IR = [glucose (mg/dL)  insulin (μU/mL)/405].
The serum levels of total cholesterol, triglycerides, and the aspartate and alanine aminotrans-
ferases were determined with a Cobas C-501 autoanalyzer (Roche Diagnostics, Mannheim,
Germany) using standardized methods.
Cell isolation. Peripheral blood mononuclear cells (PBMCs) were obtained using Ficoll-
Hypaque (Pharmacia Biotech, Uppsala, Sweden) density gradient centrifugation and resus-
pended in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma Chemical Co., Saint
Louis, MO, USA) supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, and
50 μg/mL gentamicin.
Liver tissue samples from human biopsies were incubated for 20 min at 37˚C in Hank´s bal-
anced salt solution containing 0.05% collagenase and filtered through a 70-μm mesh filter.
Liver cell suspensions were washed twice in phosphate-buffered saline, centrifugated at 2000
rpm for 5 min and resuspended in supplemented RPMI 1640.
Intracellular reactive oxygen species production. To evaluate the production of reactive
oxygen species, either PBMCs or human liver cell suspensions were incubated at 37˚C either
in the presence or absence of 200 μM linoleic acid for 60 min or with 10 nM leptin for 2 hr;
afterwards, the cells were treated with 5 μM 2’7’-dichlorofluorescein diacetate (H2DCFDA)
at 37˚C for 15 min. Then, cell surface staining was performed using phycoerythrin (PE)-conju-
gated anti-CD14 monoclonal antibodies (mAbs) (monocytes; Fig 1, pathways 3 and 4) or PE-
Fig 1. Diagram of the experimental design. Experimental design using human peripheral blood
mononuclear cells (PBMCs), human or mouse liver cells. PMA: phorbol myristate acetate, H2DCFDA: 2’7’-
dichlorofluorescein diacetate.
doi:10.1371/journal.pone.0172900.g001
Curcumin prevents immunological alterations in nonalcoholic fatty liver diseases
PLOS ONE | DOI:10.1371/journal.pone.0172900 March 3, 2017 4 / 15
conjugated anti-CD14 and peridinin-chlorophyll (PerCP)-conjugated anti-CD11b (liver mac-
rophage; Fig 1, pathway 5) mAbs.
The mean 2’,7’-dichlorofluorescein (DCF) fluorescence intensity was analyzed either in
monocytes identified by their respective forward and side scatter or in human liver macro-
phages identified by the co-expression of CD14 and CD11b. Data acquisition and analysis
were performed on a FACSCalibur flow cytometer (BD, Becton, Dickinson and Company, NJ,
USA) using FlowJo software (version 5.7.2). A stimulation index was defined as the ratio
between the mean fluorescence intensity of DCF in stimulated and non-stimulated monocytes
or macrophages.
Liver infiltrating CD4+ cells. To evaluate the percentage of CD4+ cells infiltrating the
liver, human liver cell suspensions were stained with the PerCP-conjugated anti-CD4 mAb at
4˚C for 20 min (Fig 1, pathway 6). Cells were gated based on side scatter and CD4 expression.
Intracellular cytokine production. To evaluate the production of intracellular interferon-
gamma (IFN-γ) by T cells, PBMCs were incubated in the presence or absence of 10 nM leptin
for 19 hr at 37˚C and re-stimulated for 4 hr at 37˚C with 25 ng/mL phorbol myristate acetate
(PMA) and 1 mM ionomycin in the presence of 1 mM Brefeldin A (Fig 1, pathway 1). To evalu-
ate the production of tumor necrosis factor-α (TNF-α) by monocytes, PBMCs were stimulated
in the presence of 100 nM leptin for 6 hr (Fig 1, pathway 2). Cell surface staining was performed
using anti-CD4 or anti-CD14 mAbs at 4˚C for 20 min as indicated. After the cells were fixed at
4˚C for 20 min, PE-conjugated anti-IFN-γ, anti-TNF-α or the corresponding isotype controls
were added to the suspensions, and the cells were incubated in 50 μL of permeabilization buffer
at 4˚C for 40 min. Gates were set on either lymphocytes or monocytes based on their respective
forward and side scatter properties and were used to analyze cells stained with either fluoro-
chrome-conjugated control isotypes or specific mAbs. To analyze the peripheral lymphocytes,
cells were gated based on the side scatter and CD4 expression, and IFN-γ expression was mea-
sured in the selected CD4+ population. For monocyte analysis, cells were gated in a forward vs.
side scatter dot plot (region 1). Within region 1, CD14+ cells were further gated in a side scatter
vs. FL2 dot plot (region 2), and TNF-α production was analyzed in the region 2 population.
Data acquisition and analysis were performed using flow cytometry as described above.
To quantify the effect of leptin on intracellular IFN-γ and TNF-α production, we calculated
the fold of increase index as the ratio between the percentages of either CD4+IFN-γ+ or
CD14+TNF-α+ cells among the leptin-stimulated and non-stimulated cell populations.
Quantitative polymerase chain reaction. Liver tissue was preserved in TRIZOL reagent
(GIBCO BRL, LifeTechnologies Inc., Grand Island, NY, USA) and homogenized using Omni
Tips (OMNI International, NW, Kennesaw, GA, USA). Total RNA was isolated according to
the manufacturer´s protocol and reverse transcribed using a two-step method with Super-
ScriptII First-Strand Synthesis System (Invitrogen, Life Technologies, Carlsbad, CA, USA)
with oligo (dT) primers. The forward and reverse primers were as follows: IFN-γ 5´-CTGT
TTTAGCTGCTGGCGAC-3´and 5´-GAGTGTGGAGACCATCAAGGA-3´; CCL20, 5´-AGCA
TTGATGTCACAGCCTTC-3´and 5´-TCAGTGCTGCTACTCCACCT-3´; T-box transcription
factor (T-bet), 5´-ATTGACAGTTGGGTCCAGGC-3´ and 5´-TGACTGCCTACCAGAATGCC-
3´; and glyceraldehyde 3-phosphate dehydrogenase (GADPH), 5´-cgaccactttgtcaag
ctca-3´ and 5´-acatggcctccaaggagtaa-3´. GADPH was used as an internal con-
trol. Quantitative polymerase chain reaction (qPCR) was performed on a Stratagene Mx3005p
RT-PCR Detection System (Agilent Technologies, La Jolla, CA, USA) using SYBR Green PCR
Master Mix (applied Biosystems, Life Technologies, Carlsbad, CA, USA). Relative gene expres-
sion was calculated using the 2-ΔΔCt method.
Modulatory effects of curcumin on PBMCs. PBMCs were pre-incubated with 30 μM
curcumin at 37˚C for 15 min prior to linoleic acid stimulation and incubation with H2DCFDA
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(Fig 1, pathway 4). To measure IFN-γ and TNF-α production, PBMCs were co-treated with
leptin and 10 μM curcumin at 37˚C for either 19 hr (Fig 1, pathway 1) or 6 hr (Fig 1, path-
way 2).
In vivo studies in mice
Mice, diets and general procedures. Thirty-two inbred male C57BL/6J mice (4 weeks
old) were purchased from the School of Veterinary Sciences at the University of Buenos Aires.
Of these, 16 mice were used to develop the NAFLD/nonalcoholic steatohepatitis model, and
the remaining 16 were designated as corresponding controls. Starting at 5 weeks of age, mice
were fed either normal chow (5% Kcal from fat) or a HFD (60% Kcal from fat) (OpenSource
Diets, Research Diets, Inc., New Brunswick, NJ, USA) ad libitum. After 4 weeks of feeding,
mice fed either a HFD or normal chow were randomly divided in the following 4 groups (8
mice per group): (1) HFD, (2) curcumin-treated HFD (HFD+curcumin), (3) normal chow
(NC), and (4) curcumin-treated normal chow (NC+curcumin). The curcumin-treated groups
received 2 g of curcumin/kg of diet, and the mouse body weight and food consumption were
recorded weekly. After 24 weeks of dietary treatments, an intraperitoneal glucose tolerance
test was performed, and the mice were euthanized via carbon dioxide anesthesia followed by
cervical dislocation in order to collect blood and liver tissue. Due to the limited blood volume
obtained from each mouse, the blood was used for biochemical characterization but not for
PBMC stimulation. The blood glucose concentration was determined using blood glucose
monitors (Accu-Chek Active, Roche Applied Science, Indianapolis, IN, USA) at times 0 and
120 min after an intraperitoneal injection of 2 g/kg glucose. Serum levels of total cholesterol as
well as of the aspartate and alanine aminotransferases were determined as indicated in the
"Patients and General Procedures" subsection. Hematoxylin & eosin staining was performed
for NAFLD activity score calculations, which are based on the presence of macrovesicular stea-
tosis, lobular inflammation and ballooning degeneration. Moreover, the sections were scored
for hepatic fibrosis as follows: 0, intact liver with no foci; 1, perisinusoidal or periportal fibrosis;
2, perisinusoidal and periportal fibrosis; 3, septal or bridging fibrosis; and 4, cirrhosis and
regenerative nodule formation. Masson´s trichrome staining was conducted to confirm the
presence of fibrosis.
Animals were handled in accordance with the principles of the Guide for the Care and
Use of Laboratory Animals established by the National Institutes of Health. Experimental pro-
tocols were approved by the Institutional Committee for Use and Care of Laboratory Animals
(CICUAL, School of Medicine of the University of Buenos Aires, Argentina).
Accordingly, we used the minimum number of live animals necessary to achieve our goals,
and all efforts were made to minimize pain and distress during animal husbandry and experi-
mental assessments.
Liver cell isolation. Enzymatic digestion of mouse liver tissue was performed as described
above. The resulting liver cell suspensions were centrifuged at 400 rpm for 5 min to separate
parenchymal cells (i.e., hepatocytes) from non-parenchymal cells. The non-parenchymal cell-
enriched pellets were washed twice in phosphate-buffered saline at 2000 rpm for 5 min and
resuspended in RPMI 1640 medium.
Intracellular reactive oxygen species production. To evaluate the production of reactive
oxygen species, the non-parenchymal and parenchymal fractions from digested mouse livers
were separately stimulated at 37˚C for 60 min in the presence or absence of 200 μM linoleic
acid followed by a 15-min incubation with 5 μM H2DCFDA at 37˚C (Fig 1, pathways 9 and
10). Then, cell surface staining in the non-parenchymal fraction was performed by incubating
the cells with PerCP-conjugated anti-F4/80 mAbs at 4˚C for 20 min. DCF fluorescence was
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analyzed in liver macrophages identified by the expression of the F4/80 antigen. Data acquisi-
tion and analysis were performed using flow cytometry as described above. The stimulation
index was defined as the ratio between the mean DCF fluorescence intensity in macrophages
(non-parenchymal fraction) or hepatocytes (parenchymal fraction) that were stimulated or
resting.
Intracellular cytokine production. To evaluate TNF-α production in liver macrophages,
cells were incubated for 6 hr at 37˚C in presence or absence of 100 nM leptin. Cell surface
staining was then performed using a PerCP-conjugated anti-F4/80 mAb at 4˚C for 20 min (Fig
1, pathway 8). After the cells were fixed at 4˚C for 20 min, either PE-conjugated anti-TNF-α or
the corresponding isotype control Ab was added, and cells were incubated in 50 μL of permea-
bilization buffer at 4˚C for 40 min. Data acquisition and analysis were performed as described
above. Within the resulting side scatter vs. FL3 dot plot, a gate was set for F4/80+ cells. To
quantify the effect of leptin on intracellular TNF-α production, the fold of increase index was
calculated as the ratio between the percentages of F4/80+TNF-α+ cells in leptin-stimulated and
non-stimulated cells.
Liver infiltrating CD4+ cells. Mouse non-parenchymal cell suspensions were stained
with PerCP-conjugated anti-CD4 mAb at 4˚C for 20 min (Fig 1, pathway 7), and cells were
gated based on the side scatter and CD4 expression.
Statistical analysis. GraphPad Prism software (GraphPad, San Diego, CA, USA) was used
for all the analyses. We performed either two-tailed Mann-Whitney U tests or Wilcoxon
signed rank tests to compare data between groups. The Kruskal-Wallis test was used to com-
pare data among three or more groups. For all the experiments, the values are expressed as the
median and 25th-75th interquartile ranges. Spearman’s rank correlation coefficients were used
to test the correlation between parameters.
Results
Ex vivo studies in human NAFLD
Effect of linoleic acid on reactive oxygen species production in monocytes and liver mac-
rophages. After cells were stimulated with linoleic acid, the stimulation index was significantly
increased in monocytes from patients with NAFLD than in monocytes from control subjects
[5.86 (3.43–10.67) vs. 3.24 (1.87–4.70), p = 0.036] (Fig 2A). Linoleic acid also induced reactive
oxygen species production in liver macrophages from patients with NAFLD (p = 0.001) (Fig
2B). A positive correlation between linoleic acid-induced reactive oxygen species generation in
monocytes and reactive oxygen species generation in liver macrophages was observed in
patients with NAFLD (r = 0.59, p = 0.032) (Fig 2C).
Effect of leptin on TNF-α and reactive oxygen species production in monocytes. Leptin
stimulated TNF-αα production in peripheral monocytes from control subjects and patients
with NAFLD; however, compared to the control subjects, the patients with NAFLD presented
higher fold of increase indexes [2.99 (1.91–4.03) vs. 5.04 (3.87–8.54), respectively; p = 0.004]
(Fig 3A). Similar indexes of reactive oxygen species production were observed in monocytes
from both groups [NAFLD: 1.34 (1.16–1.93), control: 1.40 (1.22–2.03), p = 0.437] (Fig 3B).
Effect of leptin on IFN-γ production in CD4+ cells. Leptin stimulated IFN-γ production
in circulating CD4+ cells from control subjects and patients with NAFLD; however, we
observed higher fold of increase indexes in patients with NAFLD than in control subjects [1.26
(1.17–1.40) vs. 1.06 (1.04–1.35), respectively; p = 0.011] (Fig 4A).
Infiltrating CD4+ cells into the liver. When intrahepatic lymphocyte subpopulations
were compared between patients with NAFLD and control subjects, the percentage of CD4+
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cells among the total cell population was higher in patients with NAFLD [2.81 (1.83–4.11) vs.
1.12 (0.70–1.25), respectively; p = 0.030] (Fig 4B).
Gene expression in liver biopsies. Compared to samples from control subjects, liver
biopsies from patients with NAFLD showed increased expression levels of IFN-γ [3.73 (2.17–
4.5) vs. 1.05 (0.61–1.7), p = 0.012], T-bet [8.67 (7.53–12.66) vs. 0.96 (0.86–1.42), p = 0.020] and
CCL20 [1.89 (1.62–2.77) vs. 1.12 (0.73–1.23), p = 0.007] (Fig 4C).
The reversal effects of curcumin. An ex vivo analysis of the effects of curcumin on
PBMCs showed a decrease in linoleic acid-induced reactive oxygen species generation
Fig 2. Effect of linoleic acid on reactive oxygen species production in human monocytes and liver macrophages. (A) The
stimulation index for reactive oxygen species production in monocytes was higher in patients with NAFLD (n = 12) than in control subjects
(n = 10). The box and whiskers indicate the non-parametric statistics: the median, lower and upper quartiles and confidence interval
around the median. A two-tailed Mann-Whitney U test was used; *p = 0.036. (B) DCF-MFI, 2’, 7’-dichlorofluorescein median
fluorescence intensity. Linoleic acid increased reactive oxygen species production in liver macrophages from patients with NAFLD
(n = 12). Lines connect the “Basal” and “Linoleic acid” values for each patient. A Wilcoxon matched-pairs signed rank test was performed;
*p = 0.001. (C) The stimulation index in monocytes and liver macrophages from patients with NAFLD were positively correlated.
Spearman´s rank correlation coefficients test was used.
doi:10.1371/journal.pone.0172900.g002
Fig 3. Effect of leptin on TNF-α and reactive oxygen species production in human monocytes. (A) The fold of increase index for
TNF-α production was higher in monocytes from patients with NAFLD (n = 10) than those from control subjects (n = 10); however, when
monocytes were stimulated with leptin, the stimulation index for reactive oxygen species production (B) was similar in patients with
NAFLD (n = 10) and control subjects (n = 10). The box and whiskers indicate the non-parametric statistics: median, lower and upper
quartiles and confidence interval around the median. A two-tailed Mann-Whitney U test was used, *p = 0.004.
doi:10.1371/journal.pone.0172900.g003
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(p = 0.011) (Fig 5A) and leptin-induced TNF-α production (p = 0.016) (Fig 5B) in monocytes
from patients with NAFLD. Curcumin lowered these parameters to levels comparable to those
in cells from control subjects (data not shown). Interestingly, curcumin also ameliorated lep-
tin-induced IFN-γ production in CD4+ cells (p = 0.048) (Fig 5C).
In vivo studies in mice
HFD-induced metabolic and liver histological alterations and the reversal effects of cur-
cumin. Compared to normal chow-fed mice, HFD mice exhibited enhanced weight gain
from week 14 to the end of the dietary treatment [40.80 (36.20–47.50) g vs. 30.90 (29.55–33.35)
g, respectively; p<0.001], (Fig 6B) and had higher serum glucose concentrations at 120 min
after a glucose injection [313 (249–382) mg/dl vs. 155 (131.8–185) mg/dl, p<0.01] (Fig 6C) at
the end of the dietary treatment. Higher total cholesterol levels were also observed in the HFD
[150 (103–172) mg/dl, p<0.05] and HFD+curcumin [149(126.5–188) mg/dl, p<0.05] groups
than in the normal chow-fed mice [98 (82–102.5) mg/dl] (Fig 6D). However, the levels of tri-
glycerides as well as of the aspartate and alanine aminotransferases were similar among all the
groups (data not shown).
Hematoxylin & eosin staining revealed steatohepatitis with macrovesicular and microvesi-
cular liver steatosis, scattered foci of lobular inflammation and ballooning degeneration in the
Fig 4. The effects of leptin on IFN-γ production and T cell-associated alterations in liver samples from
patients with NAFLD. (A) The fold of increase index for IFN-γ production in leptin-stimulated circulating
CD4+ cells was higher in patients with NAFLD (n = 10) than in control subjects (n = 10; *p = 0.011). (B) The
percentage of CD4+ cells among the total non-parenchymal cell population was higher in patients with NAFLD
(n = 10) than in control subjects (n = 10), *p = 0.030. (C) Compared with control subjects (n = 9), patients with
NAFLD (n = 9) showed increased hepatic mRNA expression levels of IFN-γ (*p = 0.012), T-bet (*p = 0.020)
and CCL20 (*p = 0.007) as measured by quantitative PCR. The 2-ΔΔCt method was used to calculate the
mRNA fold change. The box and whiskers indicate the non-parametric statistics: the median, lower and upper
quartiles and confidence interval around the median. A two-tailed Mann-Whitney U test was used for the
statistical analysis.
doi:10.1371/journal.pone.0172900.g004
Fig 5. The reversal effects of curcumin on peripheral immunological cells. Ex vivo curcumin treatment
of PBMCs from patients with NAFLD resulted in decreases in (A) linoleic acid-induced reactive oxygen
species generation (n = 9, *p = 0.011) and (B) leptin-induced TNF-α production (n = 9, *p = 0.016) by
monocytes. (C) Ex vivo curcumin treatment of PBMCs from patients with NAFLD resulted in decreased IFN-γ
production in CD4+ cells (n = 9, *p = 0.048). Lines connect the “Linoleic acid” and “Linoleic acid+Curcumin”
stimulation indexes or the “Leptin” and "Leptin+Curcumin" fold of increase indexes for each patient. A
Wilcoxon matched-pairs signed rank test was performed.
doi:10.1371/journal.pone.0172900.g005
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livers from HFD-fed mice (Fig 6A). Hematoxylin & eosin scoring and Masson’s trichrome
staining revealed that 70% of the HFD-fed mice exhibited signs of mild perisinusoidal fibrosis.
In contrast, none of the NC mice developed fibrosis.
Compared to the non-supplemented diets, in vivo curcumin supplementation prevented
weight gain [30.60 (30.45–33.05) g] among the HFD group (p<0.05) (Fig 6B) and improved
glucose elimination from the blood of HFD mice [HFD+curcumin: 219 (194.5–276) mg/dl,
p<0.05, vs. HFD] (Fig 6C). Curcumin administration also prevented liver injury by reducing
steatosis, inflammation and ballooning degeneration (Fig 6A). Furthermore, only 20% of HFD
mice supplemented with curcumin exhibited signs of mild perisinusoidal fibrosis.
Fig 6. HFD-induced metabolic and histological alterations in the liver and the reversal effects of
curcumin. (A) Top: Hematoxylin and eosin staining of liver sections from normal chow (NC)-fed and high-fat
diet (HFD)-fed mice with or without curcumin supplementation (10X and 40X magnification). Curcumin
prevented HFD-induced steatosis, ballooning and liver inflammation. Bottom: Masson’s trichrome staining of
liver sections from HFD-fed mice reveals signs of mild perisinusoidal fibrosis (10X and 40X magnification). (B)
Body weight gain in NC- and HFD-fed mice with or without curcumin supplementation, starting at week 4
(arrow) (*p<0.05, **p<0.01 and ***p<0.001, HFD vs. NC). Curcumin prevented HFD-induced weight gain
(#p<0.05, ##p<0.01 and ###p<0.001, HFD vs. HFD+curcumin). (C) The blood glucose concentrations were
measured upon conclusion of the dietary treatments, and glycemia was determined at basal conditions
(Basal) and after glucose administration. Left: a similar blood glucose concentration was observed among the
four groups. Right: hyperglycemia was observed in HFD-fed mice at 120 min after an intraperitoneal glucose
injection (2 g/kg). Curcumin ameliorated the hyperglycemic conditions. (*p<0.01). (D) Total serum cholesterol
levels were measured upon conclusion of the dietary treatments. The HFD induced higher levels of
cholesterol than the normal chow regardless of curcumin administration (*p<0.05). The box and whiskers
show the non-parametric statistics: the median, lower and upper quartiles and confidence interval around the
median. The Kruskal-Wallis test with Dunn’s post-test was performed.
doi:10.1371/journal.pone.0172900.g006
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Effect of linoleic acid on reactive oxygen species production in liver cells and the rever-
sal effects of curcumin. Upon stimulation with linoleic acid, liver macrophages from HFD-
fed mice showed a higher production of reactive oxygen species than macrophages from NC
mice [3.88 (3.46–7.63) vs. 2.95 (2.48–3.42) p<0.05] (Fig 7A). However, liver macrophages
treated with curcumin showed a reduction in the linoleic acid-induced increase in reactive
oxygen species production [2.49 (2.12–3.30), p<0.05, Fig 7A]. Linoleic acid stimulation of
hepatocytes from all the experimental groups resulted in similar stimulation indexes for reac-
tive oxygen species production (Fig 7B).
Effects of leptin on TNF-α production in liver macrophages and the reversal effect of
curcumin. When stimulated with leptin, liver macrophages from HFD-fed mice showed a
more profound increase in TNF-α production than NC mice [1.73 (1.38–1.80) vs. 1.24 (1.21–
1.30), p<0.05]. Curcumin prevented the leptin-induced increase in TNF-α production [1.21
(1.15–1.28), p<0.05] in liver macrophages (Fig 7C).
Infiltrating CD4+ cells in the liver and the reversal effect of curcumin. Flow cytometry
of non-parenchymal cells in the liver showed that the percentage of CD4+ cells was higher in
HFD-fed mice than in normal chow-fed mice [1.42 (1.34–1.85) vs. 0.24 (0.13–0.54), p<0.05].
However, the recruitment of CD4+ cells into the liver was attenuated in curcumin-treated
HFD-fed mice [0.52 (0.29–0.83), p<0.01, HFD+curcumin vs. HFD] (Fig 7D).
Fig 7. Curcumin effects on linoleic acid- and leptin-induced the production of reactive oxygen
species and cytokines as well as the infiltration of CD4+ cells in HFD-fed mice. (A) After they were
treated with linoleic acid ex vivo, liver macrophages from HFD-fed mice showed a higher stimulation index for
reactive oxygen species production (*p<0.05 vs. normal chow-fed mice). In vivo curcumin administration of
HFD-fed mice (HFD+curcumin) prevented the increase in the stimulation index (*p<0.05 vs. HFD-fed mice).
(B) Ex vivo linoleic acid stimulation of hepatocytes from all the experimental groups resulted in similar
stimulation indexes for reactive oxygen species production. (C) TNF-α production induced by ex vivo leptin
treatment was higher in liver macrophages from HFD-fed mice (*p<0.05 vs. normal chow-fed mice). In vivo
curcumin treatment of HFD-fed mice also prevented the increase in TNF- α production (*p<0.05, HFD
+curcumin vs. HFD). (D) The percentage of CD4+ cells among the non-parenchymal cell populations was
higher in HFD-fed mice (*p<0.01 vs. normal chow-fed mice). In vivo curcumin treatment also prevented the
increase in CD4+ cell recruitment (*p<0.01, HFD+curcumin vs. HFD). The box and whiskers show the non-
parametric statistics: the median, lower and upper quartiles and confidence interval around the median. The
Kruskal-Wallis test with Dunn’s post-test was performed.
doi:10.1371/journal.pone.0172900.g007
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Discussion
Our present findings concerning human NAFLD indicate that linoleic acid exacerbated reac-
tive oxygen species generation in monocytes and liver macrophages and that leptin promoted
increased TNFα production in monocytes coupled with more CD4+ cell differentiation into
Th1 cells. Ex vivo curcumin treatment of PBMCs from patients with NAFLD showed a rever-
sion of the hyperresponsiveness to linoleic acid and leptin observed in monocytes and CD4+
cells. The response of these immune cells may reveal higher baseline activity of pro-inflamma-
tory enzymes and signaling pathways within these cells. For example, linoleic acid-induced
acceleration of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase assembly
and/or co-activation of protein kinase C [25] and leptin-induced activation of receptor-associ-
ated kinases, insulin receptor substrate-1 and associated signaling pathways [26] might con-
tribute to the observed increases in reactive oxygen species, TNF-α production and Th1
differentiation. We observed a positive correlation between linoleic acid-induced reactive
oxygen species generation in monocytes and the number of liver macrophages from patients
with NAFLD. Although this correlation does not directly add a predictive value to peripheral
linoleic acid-induced reactive oxygen species production, this observation warrants further
investigation.
Curcumin exerts an ex vivo protective effect against linoleic acid- and leptin-induced
inflammatory stimuli which may be mediated by downregulating the expression of transcrip-
tion factors and reducing the activity of associated signaling pathways [19].
The analysis of gene expression and intrahepatic accumulation of CD4+ cells was addressed
to evaluate T cell-related alterations in the liver. T-bet is a critical regulator of the expression of
chemokines and their corresponding receptors and induces Th1 differentiation of CD4+ lym-
phocytes [27]. Lymphocyte recruitment is an essential process associated with NAFLD pro-
gression, and enhanced infiltration of CD4+ cells coupled with elevated expression levels of T-
bet, IFN-γ and CCL-20 in liver biopsies indicate a prevailing inflammatory state in patients
with NAFLD.
The in vivo approach of this study involved the development of an experimental model that
reproduced the primary characteristics of nonalcoholic steatohepatitis in humans. Mice fed a
HFD developed steatohepatitis with mild fibrosis, exhibited enhanced weight gain, and pre-
sented higher total cholesterol levels and poor elimination of glucose from the blood. In con-
trast, despite a great number of studies describing elevated hepatic transaminase levels in
HFD-induced experimental NAFLD, we did not observe increased levels of either aspartate or
alanine aminotransferases. However, our results were in agreement with a report that observed
hepatic lipid accumulation and mild fibrosis with no changes in the aspartate and alanine ami-
notransferase levels in rats fed a HFD [28]. We also performed experiments with our mouse
model that corresponded to most of the human studies. As in the livers from patients with
NAFLD, enhanced reactive oxygen species generation and TNF-α production by mouse liver
macrophages revealed an overall hyperactive state in the HFD-fed group. This condition may
result from the diet-induced elevation of the intrahepatic levels of pro-inflammatory cytokines
and glucose, which might promote the activation of NADPH oxidase [29] and the hyperre-
sponsiveness to pro-inflammatory mediators such as linoleic acid and leptin. Reactive oxygen
species production by linoleic acid-stimulated hepatocytes is probably associated with the high
intrinsic antioxidant capacity of this cell type [30]. As in human NAFLD, increased intrahepa-
tic accumulation of CD4+ cells was found to be an immunological alteration in HFD-fed mice.
In vivo curcumin administration interfered with the development of distinctive characteris-
tics associated with the NAFLD/nonalcoholic steatohepatitis phenotype, such as obesity and
glucose intolerance, and improved histological alterations, including fibrosis and the
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intrahepatic accumulation of CD4+ cells. The overall beneficial effects of curcumin on the
development of HFD-induced nonalcoholic steatohepatitis may result from its direct interac-
tion with different metabolically active tissues [31]. However, because HFD-fed mice devel-
oped obesity and glucose intolerance and these metabolic alterations influence liver injury and
nonalcoholic steatohepatitis-associated fibrosis [32], we cannot disregard the possibility that
local histological improvement may be an effect secondary to the systemic properties of curcu-
min. The lack of an exacerbated response of liver macrophages from the HFD+curcumin
group to pro-inflammatory mediators may result from the effects of curcumin on multiple tar-
gets during in vivo mouse treatments [19].
An important strength of this study is the similarities between the developed animal model
and the primary general features of human nonalcoholic steatohepatitis. Nevertheless, we rec-
ognize several limitations of our study. First, we used supraphysiological concentrations of lep-
tin and linoleic acid in the ex vivo human experiments [33, 34]. Second, we used PBMCs and
liver cell suspensions rather than isolated monocytes, T cells and macrophages. Third, the
restrictions imposed by the limited blood volume and the small size of percutaneous liver biop-
sies resulted in insufficient samples to perform each assay for every subject. Regarding control
livers, we could only utilize biopsies that were removed from patients who required a diagnos-
tic test; these biopsies were performed to rule out other diagnoses, and the samples ended up
being control livers. Thus, another limitation was the bias that could have been established in
selecting patients who underwent anti-reflux surgery or cholecystectomy as the source of con-
trol livers.
Based on a post hoc analysis using GPower 3.1.9.2 (Universita¨t Du¨sseldorf, Germany), the
power of the statistically significant results from human studies fell within the acceptable range
of 0.551 to 1.000 (S1 Table). In the case of the leptin-induced effect on CD4+ circulating cells
(which was calculated with the lowest statistical power), we have used our results as prelimi-
nary data and calculated that 2–3 times more patients are needed to reach a value of at least
0.800.
Conclusions
We have demonstrated the remarkable pro-inflammatory and pro-oxidant influence of lino-
leic acid and leptin in human and mouse NAFLD/nonalcoholic steatohepatitis and showed
that curcumin prevented the development of immunological alterations in this disease. A pre-
ventive treatment with curcumin might target circulating monocytes and liver macrophages as
well as peripheral and hepatic CD4+ cells. The translational potential of these results requires
additional research.
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S1 Table. Statistical power of human studies. The power of the human studies was calculated
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